Donald Yacktman
Yacktman Asset Management
Donald Yacktman Abbott Laboratories stake
total: 148
Yacktman Asset Management ABT trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2018 Q3
- Held for:
- 2 quarters
- Latest activity:
- 2019 Q1
According to 2026 Q2 report, Donald Yacktman doesn't hold any Abbott Laboratories (ABT) shares. To date, the estimated cost basis is nearly $73.21 for "buy" trades and estimated average "sell" price is $72.5. Yacktman Asset Management first purchased ABT in 2018 Q3, initially acquiring 2,800 shares. Since the initial investment in Abbott Laboratories (ABT), Yacktman Asset Management has made 1 more transaction.
When did Donald Yacktman sell Abbott Laboratories (ABT)?
Donald Yacktman sold off the entire Abbott Laboratories (ABT) position in 2019 Q1.
When did Donald Yacktman buy Abbott Laboratories (ABT)?
Donald Yacktman first invested in Abbott Laboratories (ABT) in 2018 Q3 at the reported quarter-end price of $73.21 per share.
What's the cost basis of Yacktman Asset Management's ABT stake?
The estimated cost basis for Abbott Laboratories (ABT) stake is around $73.21 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $73.21
- Weighted AVG sell price:
- $72.50
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.